WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader ...

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate ...

NiKang Therapeutics has concluded the first cohort dosing in the open-label Phase I trial of NKT3964 as a monotherapy for ...

We found that the expression levels of CDK2, Cyclin E1 (CCNE1) and Cyclin E2 (CCNE2) were decreased in BD-treated cells in a dose- and time- dependent manner (Figures 2C,D). These results suggest that ...

The exact molecular functions of Polo-like kinase 1 (PLK1) in mitotic prophase are not fully understood. This study shows that PLK1 inhibition delays activation of CDK1-cyclin B and halts cells for ...

Now, a study published in Cell Communication and Signaling describes ... β/δ can regulate InsRβ levels in mouse muscle and myotubes in culture. The results show that deletion of the PPARβ ...

The important paper provides compelling evidence that the gene hkb controls the development of the salivary gland of Drosophila by controlling a cell cycle and cell death. The work extends and ...

The identification of the tumor suppressor RBL2/p130 as a substrate of cyclin F/SCF adds a new level of understanding about the role of this ubiquitin ligase in cell cycle control and identifies a ...

disease severity and Cyclin E1 expression. These data indicate that PRMT5 promotes G1/S cell cycle progression and suggest that this effect influences disease severity and/or progression in the animal ...